ARS Pharmaceuticals (NASDAQ: SPRY) insider transactions
In the twelve months to 10 November 2026, executives and directors of ARS Pharmaceuticals reported 5 open-market sales of 216,563 shares ($1.9m) and 0 open-market purchases, by 4 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 12 June 2026 | Fitzpatrick Alexander A | Chief Legal Officer | Open-market sale, 10b5-1 plan | −3,355 | $10.00 | 90,910 | Form 4 |
| 12 June 2026 | Karas Eric | Chief Commercial Officer | Option exercise, 10b5-1 plan | +25,000 | $1.50 | 37,176 | Form 4 |
| 12 June 2026 | Karas Eric | Chief Commercial Officer | Open-market sale, 10b5-1 plan | −25,000 | $10.00 | 12,176 | Form 4 |
| 13 November 2025 | Dorsey Brian | Chief Operating Officer | Option exercise | +21,828 | $0.64 | 32,617 | Form 4 |
| 13 November 2025 | Dorsey Brian | Chief Operating Officer | Open-market sale | −21,828 | $8.71 | 10,789 | Form 4 |
| 12 November 2025 | Shah Pratik | Director | Gift | −250,000 | — | 4,574,554 | Form 4 |
| 12 November 2025 | Shah Pratik | Director | Gift | −100,000 | — | 4,474,554 | Form 4 |
| 12 November 2025 | Chakma Justin | Chief Business Officer | Option exercise | +30,000 | $0.84 | 166,380 | Form 4 |
| 12 November 2025 | Chakma Justin | Chief Business Officer | Open-market sale | −30,000 | $8.91 | 136,380 | Form 4 |
| 12 November 2025 | Chakma Justin | Chief Business Officer | Open-market sale | −136,380 | $8.86 | 0 | Form 4 |
| 21 August 2025 | Scott Kathleen D. | Chief Financial Officer | Option exercise, 10b5-1 plan | +12,500 | $1.50 | 22,542 | Form 4 |
| 21 August 2025 | Scott Kathleen D. | Chief Financial Officer | Open-market sale, 10b5-1 plan | −12,500 | $15.00 | 10,042 | Form 4 |
| 21 August 2025 | Lowenthal Richard E | President and CEO | Open-market sale, 10b5-1 plan | −50,000 | $14.49 | 1,196,494 | Form 4 |
| 20 August 2025 | Tanimoto Sarina | Chief Medical Officer | Open-market sale, 10b5-1 plan | −37,656 | $14.09 | 1,247,447 | Form 4 |
| 19 August 2025 | Tanimoto Sarina | Chief Medical Officer | Open-market sale, 10b5-1 plan | −12,344 | $14.03 | 1,285,103 | Form 4 |
| 1 July 2025 | Karas Eric | Chief Commercial Officer | Option exercise, 10b5-1 plan | +15,000 | $1.50 | 25,315 | Form 4 |
| 1 July 2025 | Karas Eric | Chief Commercial Officer | Open-market sale, 10b5-1 plan | −15,000 | $16.99 | 10,315 | Form 4 |
| 27 June 2025 | Flynn James E | — | Open-market sale | −370,075 | $18.46 | 4,887,254 | Form 4 |
| 27 June 2025 | Flynn James E | — | Open-market sale | −370,074 | $18.46 | 4,887,254 | Form 4 |
| 18 June 2025 | Karas Eric | Chief Commercial Officer | Option exercise, 10b5-1 plan | +15,000 | $1.50 | 22,696 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the ARS Pharmaceuticals page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.